Sign in
Taking people in United StatesNo phase

Home airway clearance device for people with bronchiectasis

Tests the BiWaze Clear device for airway clearance in people with bronchiectasis.

Key facts

Who runs it
Delve Health
Where
New Haven, Orlando, Port Saint Lucie, Tamarac, and Tampa, United StatesSee the 5 sites
Trial code
Registry title
OLE Therapy With BE Patients in Home Care Study
Status
Recruiting
People taking part
85 people, planned
Started
20 May 2025
Planned end
31 Aug 2026
Type of study
Interventional
Treatments tested
  • BiWaze Clear System
Record updated
14 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people over 5 years old with bronchiectasis (widened, damaged airways) who have had recent flare-ups. They will use the BiWaze Clear device for airway clearance for 6 months instead of their previous therapy.

Age
Older than 5 years.
Sex
All sexes can join.
Disease stage
Bronchiectasis, including people with cystic fibrosis with documented bronchiectasis. At least 1 flare-up in the past 6 months, or 2 or more in the past 12 months, that needed unplanned medical care. Breathing must be stable at screening.
Earlier treatment
No OLE (oscillating lung expansion) therapy in the past 12 months.

Main reasons for not taking part

  • Rapidly progressing NMD (neuromuscular disease).
  • Expected hospital stay within the next six months, or a collapsed lung (pneumothorax) in the past 6 months.
  • Current smoker or tobacco use within the last 30 days.
  • Pregnancy or breastfeeding.
  • Serious other conditions, such as active cancer or severe heart, lung, liver, kidney or nerve disease, or allergy to device materials.

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • To be eligible to participate in this study, an individual must meet all of the following criteria:
  • Patients aged > 5 years old
  • History of one or more respiratory exacerbations in the past 6 months or two or more respiratory exacerbations in the past 12 months, which required unplanned or unscheduled medical intervention
  • Ability to perform BiWaze Clear therapy as prescribed
  • Clinically stable respiratory status at the time of screening
  • Bronchiectasis diagnosis (including patients with cystic fibrosis with documented bronchiectasis)
  • Signed informed consent (and Child assent if minor subject)

Who cannot take part

  • Use of OLE therapy within the past 12 months
  • Inability or unwillingness to perform OLE therapy or study procedures as required
  • History of pneumothorax within the past 6 months
  • Any medical conditions deemed by investigators to have a significant impact on the study results, e.g., active cancer, severe cardiovascular, severe progressive pulmonary disease, liver, kidney, or neurological conditions
  • Known allergies to materials used in OLE device
  • An individual who meets any of the following criteria will be excluded from participating in this study:
  • Diagnosis with rapidly progressing NMD
  • Anticipated requirement for hospitalization within the next six months
  • Currently enrolled in a different study
  • Current smoker or tobacco use within the last 30 days
  • Pregnancy or Breastfeeding
  • Inability to comply with the treatment protocol or study procedures

Where in United States

  • Yale School of MedicineNew Haven, United StatesContact: Ashley LosierTaking people
  • Central Florida Pulmonary Group, P.A.Orlando, United StatesContact: Daniel T. Layish, MD,FACP,FCCP,FAASMTaking people
  • Treasure Coast Medical Research Group, LLCPort Saint Lucie, United StatesContact: Mark Pamer, MDTaking people
  • Metropolitan Clinical ResearchTamarac, United StatesContact: Hector Vazquez, MDTaking people
  • University of South Florida (Tampa General Hospital)Tampa, United StatesContact: Chak Sriaroon, MDTaking people

About the trial

What the trial wants to find out

The study will examine how the performance of Oscillating Lung Expansion (OLE) therapy affects the respiratory health of patients with Bronchiectasis (BE).

Read full original descriptionShow less

The patient will use the BiWaze Clear system for their airway clearance therapy, instead of their previously prescribed therapy. BiWaze Clear is an FDA-cleared respiratory therapy for assisting patients in loosening and mobilizing secretions as well as treating and preventing atelectasis by providing lung expansion and high-frequency oscillation therapies, combined with aerosol delivery.

The patient will perform airway clearance with BiWaze Clear as prescribed. The system uses a disposable breathing circuit, which is a single patient use, disposable circuit.

The treatment duration is 6 months . The BiWaze Clear System is indicated for the mobilization of secretions, lung expansion therapy, the treatment and prevention of pulmonary atelectasis and has the ability to provide supplemental oxygen when used with an oxygen supply.

The group in the trial

  • BiWaze Study Device treatment single ArmTreatment being tested

    All patients will be assigned to a single treatment arm utilizing BiWaze Clear System

    Treatment: BiWaze Clear System

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Oscillating Lung Expansion (OLE) Therapy in the Bronchiectasis Patients (BE) Home Care Study Protocol
Plain-language title
Home airway clearance device for people with bronchiectasisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
14 April 2026